Navigation Links
New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extent than losartan.(1)

Commenting on the results, Prof. Ellen Burgess, Foothills Hospital in Calgary, Canada said "The AMADEO results are encouraging for an increasing number of patients with type 2 diabetes because they suggest that telmisartan could improve renoprotection. It is particularly interesting that the observed effect was seen despite the study being controlled for blood pressure." She continued, "telmisartan has already shown superior blood pressure lowering compared to losartan and, in AMADEO, patients were allowed to take other medication, if needed, to ensure similar blood pressure in both treatment groups. This suggests that the protective benefits seen with telmisartan here are an additional attribute beyond its established blood pressure lowering effects."

Diabetic nephropathy is a kidney disease that occurs in approximately one third of patients with diabetes mellitus(2). These study results could, therefore, have a positive impact on millions of type 2 diabetes patients as well as healthcare systems worldwide. The prevalence of diabetes is projected to increase at an alarming rate from 171 million in 2000 to 366 million by 2030(3), with the upsurge in obesity closely linked to increased type 2 diabetes. Over time, diabetic nephropathy can lead to end-stage renal disease, a serious condition that needs dialysis and increased medical care and resources. End-stage renal disease has tripled in prevalence over the past two decades(4) and has huge associated healthcare costs, predicted to be US$28 billion by 2010 in the US alone(5).
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Pieris AG presented the results ... most advanced Anticalin ® , PRS-050, an anti-VEGF ... Conference held in San Francisco, California.  The dose-escalation ... tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... for the third quarter ended September 30, 2011. ... revenues were RMB124.7 million ($19.6 million)(A) in the third quarter ...
Cached Medicine Technology:Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 2Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 3Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15
(Date:7/26/2014)... (PRWEB) July 26, 2014 ... recently updated by Vkool.com, this is a ... safe methods for treating all types of ...     Tinnitus due to Ménière's ... ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... Columbus, OH (PRWEB) July 26, 2014 The ... medical guidelines list that includes a new medication guide for ... as a serious side-effect of taking the topical low testosterone ... notes that AbbVie Inc., the makers of the low testosterone ... include symptoms of pain, swelling or redness as signs of ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... updated by Vkool.com, this is a comprehensive guide that ... unwanted tattoos . This book also teaches them ... imitate common medical procedures in their own home for ... that "Get Rid Tattoo Naturally" book includes step-by-step tutorials ...
(Date:7/25/2014)... Texas (PRWEB) July 26, 2014 ... and China Gel Permeation Chromatography Industry” is ... the Global and China Gel Permeation Chromatography ... Chromatography information, including Gel Permeation Chromatography definition, ... well as industry overview. This research covers ...
(Date:7/25/2014)... July 25, 2014 A federal judge ... in two DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ... the claims to go before a jury on September ... rendered on July 18th, U.S. District Judge Ed Kinkeade ... two Plaintiffs’ claims may proceed to trial against Johnson ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... -- People with heart conditions who take vitamins may be ... according to a new study. Researchers from the Intermountain ... heartbeat -- known as atrial fibrillation -- what they knew ... were also asked how well they followed their prescription for ...
... Healthy, new heart cells have been generated by animals ... derived from cardiac biopsies or "cardiospheres," according to research ... and Biomedical Sciences. , The research is being ... the American Heart Association in Orlando. , The UB ...
... which can develop into any cell type in the ... drive their metabolic activities. In contrast, mature ... mitochondria to convert sugar and oxygen into carbon dioxide ... phosphorylation for their metabolic needs. How cells ...
... surgical techniques on toy animals before having to perform operations ... the same time, the use of laboratory animals is minimised. ... - the Faculty of Life Sciences at the University of ... the ,teddy laboratory, strengthens learning and the teaching environment. ...
... -- Preliminary trials indicate that a new drug designed ... shows considerable promise, both on its own and in ... is part of a class of so-called "cholesteryl ester ... CETP medication to undergo testing as a means to ...
... Reinberg HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay ... the statin drug Zocor (simvastatin) to help lower their cholesterol ... Even though niacin appeared to increase HDL cholesterol -- the ... in the blood, it did not reduce the risk of ...
Cached Medicine News:Health News:Heart Patients Using Vitamins May Take Meds Improperly 2Health News:Heart Patients Using Vitamins May Take Meds Improperly 3Health News:New heart cells increase by 30 percent after stem cell infusion 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 3Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 4Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Cholesterol Drug Shows Promise in Early Research 2Health News:Cholesterol Drug Shows Promise in Early Research 3Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Select ... art, automated microbial detection system ... fluid and mycobacteria culturing. This ... data management or laboratory information ...
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid One, a microbial identification system....
Medicine Products: